Alcohol Use Disorder Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Alkermes, Teva Pharma, BioCorRx, Inc., Adial Pharma, ADDEX THER

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Alcohol Use Disorder pipeline constitutes 30+ key companies continuously working towards developing 30+ Alcohol Use Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Alcohol Use Disorder Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alcohol Use Disorder Market.

The Alcohol Use Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Alcohol Use Disorder Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Alcohol Use Disorder treatment therapies with a considerable amount of success over the years. Alcohol Use Disorder Key players such as - Pear Therapeutics, Cybin, Lohocla Research, BioXcel Therapeutics, Pop Test Oncology, Dicerna Pharmaceuticals, Astellas Pharma, Kinnov Therapeutics, MediciNova, Adial Pharmaceuticals, and others, are developing therapies for the Alcohol Use Disorder treatment

*
Alcohol Use Disorder Emerging therapies such as - Pear-009, CYB003, Nezavist, BXCL501, PT150, DCR-AUD, ASP8062, KT 110, Ibudilast, AD04, and others are expected to have a significant impact on the Alcohol Use Disorder market in the coming years.

*
Ibb has received a patent from the United States Patent and Trademark Office, expanding coverage to a wider array of genotype combinations identified through its proprietary genetic test used for the targeted treatment of Alcohol Use Disorder (AUD) with its lead investigational therapy, AD04. In the same month, the company also shared positive topline results from a pharmacokinetics (PK) study of AD04. These findings will help refine the design parameters for the upcoming Phase 3 clinical trial of the drug.

*
In August 2024, Adial Pharmaceuticals has partnered with Boudicca to support the development of technical and regulatory strategies for its companion diagnostic genetic test.

*
In July 2024, The US FDA approved the IND application for the CMND-100 oral capsule, allowing the company to commence a Phase I/IIa clinical trial in the US for Alcohol Use Disorder (AUD). Additionally, Clearmind Medicine formed a strategic partnership with JS First Sdn. Bhd. to identify global manufacturers and distributors for its MEAI-based alcohol substitute beverages, supporting its international expansion. In June 2024, Adial Pharmaceuticals published the previously reported findings from its Phase III ONWARD study in the *European Journal of Internal Medicine*.

Alcohol Use Disorder Overview

Alcohol use disorder (AUD) is a chronic and relapsing condition characterized by an inability to control or limit alcohol consumption despite its negative consequences on physical health, mental well-being, and social functioning. It is considered a spectrum disorder, with varying degrees of severity ranging from mild to severe.

Get a Free Sample PDF Report to know more about Alcohol Use Disorder Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/alcohol-use-disorder-pipeline-insight [https://www.delveinsight.com/report-store/alcohol-use-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Route of Administration

Alcohol Use Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Infusion

*
Intradermal

*
Intramuscular

*
Intranasal

*
Intravenous

*
Oral

*
Parenteral

*
Subcutaneous

*
Topical

*
Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

*
Gene therapies

*
Small molecule

*
Vaccines

*
Polymers

*
Peptides

*
Monoclonal antibodies

*
Product Type

Alcohol Use Disorder Pipeline Therapeutics Assessment

*
Alcohol Use Disorder Assessment by Product Type

*
Alcohol Use Disorder By Stage and Product Type

*
Alcohol Use Disorder Assessment by Route of Administration

*
Alcohol Use Disorder By Stage and Route of Administration

*
Alcohol Use Disorder Assessment by Molecule Type

*
Alcohol Use Disorder by Stage and Molecule Type

DelveInsight's Alcohol Use Disorder Report covers around 5+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Alcohol Use Disorder product details are provided in the report. Download the Alcohol Use Disorder pipeline report to learn more about the emerging Alcohol Use Disorder therapies [https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Alcohol Use Disorder Therapeutics Market include:

Key companies developing therapies for Alcohol Use Disorder are - Alkermes, Teva Pharmaceutical Industries Ltd., BioCorRx, Inc., Adial Pharmaceuticals, ADDEX THERAPEUTICS, Kinnov Therapeutics, Opiant Pharmaceuticals, Ethypharm, Omeros Corporation, Montisera Ltd., and others

Emerging Alcohol Use Disorder Drugs Under Different Phases of Clinical Development Include:

*
Pear-009: Pear Therapeutics

*
CYB003: Cybin

*
Nezavist: Lohocla Research

*
BXCL501: BioXcel Therapeutics

*
PT150: Pop Test Oncology

*
DCR-AUD: Dicerna Pharmaceuticals

*
ASP8062: Astellas Pharma

*
KT 110: Kinnov Therapeutics

*
Ibudilast: MediciNova

*
AD04 : Adial Pharmaceuticals

Alcohol Use Disorder Pipeline Analysis:

The Alcohol Use Disorder pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Alcohol Use Disorder with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alcohol Use Disorder Treatment.

*
Alcohol Use Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Alcohol Use Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alcohol Use Disorder market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Alcohol Use Disorder drugs and therapies [https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Alcohol Use Disorder Pipeline Market Drivers

*
Increasing Awareness

*
Increasing research and development

*
Initiative taken by market players

Alcohol Use Disorder Pipeline Market Barriers

*
Less Treatment Utilization

*
Side Effects of The Current Therapies

Scope of Alcohol Use Disorder Pipeline Drug Insight

*
Coverage: Global

*
Key Alcohol Use Disorder Companies: Pear Therapeutics, Cybin, Lohocla Research, BioXcel Therapeutics, Pop Test Oncology, Dicerna Pharmaceuticals, Astellas Pharma, Kinnov Therapeutics, MediciNova, Adial Pharmaceuticals, and others

*
Key Alcohol Use Disorder Therapies: Pear-009, CYB003, Nezavist, BXCL501, PT150, DCR-AUD, ASP8062, KT 110, Ibudilast, AD04, and others

*
Alcohol Use Disorder Therapeutic Assessment: Alcohol Use Disorder current marketed and Alcohol Use Disorder emerging therapies

*
Alcohol Use Disorder Market Dynamics: Alcohol Use Disorder market drivers and Alcohol Use Disorder market barriers

Request for Sample PDF Report for Alcohol Use Disorder Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1

Alcohol Use Disorder Report Introduction

2

Alcohol Use Disorder Executive Summary

3

Alcohol Use Disorder Overview

4

Alcohol Use Disorder- Analytical Perspective In-depth Commercial Assessment

5

Alcohol Use Disorder Pipeline Therapeutics

6

Alcohol Use Disorder Late Stage Products (Phase II/III)

7

Alcohol Use Disorder Mid Stage Products (Phase II)

8

Alcohol Use Disorder Early Stage Products (Phase I)

9

Alcohol Use Disorder Preclinical Stage Products

10

Alcohol Use Disorder Therapeutics Assessment

11

Alcohol Use Disorder Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Alcohol Use Disorder Key Companies

14

Alcohol Use Disorder Key Products

15

Alcohol Use Disorder Unmet Needs

16

Alcohol Use Disorder Market Drivers and Barriers

17

Alcohol Use Disorder Future Perspectives and Conclusion

18

Alcohol Use Disorder Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alcohol-use-disorder-pipeline-2025-therapies-under-investigation-clinical-trials-milestones-and-fda-approvals-by-delveinsight-alkermes-teva-pharma-biocorrx-inc-adial-pharma-addex-ther]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.